ClinicalTrials.gg
RecruitingNCT06288191Updated Jul 8, 2026

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

A Phase 2 interventional study of Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination in Cutaneous Squamous Cell Carcinoma, sponsored by Melanoma Institute Australia. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Melanoma Institute Australia · Phase 2, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate (pCR) and recurrence-free survival.

Read the detailed description

This is a phase 2, open label, single cohort, single centre, clinical trial of neoadjuvant immunotherapy with dual inhibition of PD-1 and LAG-3 immune checkpoint pathways. The hypothesis is that neoadjuvant therapy produces a higher pathological response rate (pCR) and a longer recurrence-free survival in a cohort of treatment-naïve patients with resectable stage II to IV (M0) cutaneous squamous cell carcinoma compared to neoadjuvant cemiplimab monotherapy in Checkmate 358 (n=123, NCT04154943 , historical control).

02

Conditions studied

  • Cutaneous Squamous Cell Carcinoma

Keywords

  • neoadjuvant
  • immunotherapy
  • pathological response
03

In context

Lead sponsor

Melanoma Institute Australia is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Written
  3. confirmed, resectable stage II to IV cutaneous squamous cell carcinoma defined as:

    Non-head and neck cuSCC:

    1. stage II (T2, N0, M0)
    2. stage III (T3, N0, M0; or T1-3, N1, M0)
    3. stage IV (T1-3, N2 or N3, M0; or T4a or T4b, any N, M0)

    Cutaneous head and neck CC:

    1. stage II (T2, N0, M0)
    2. stage III (T3, N0, M0)
    3. stage IV (T4a or T4b, any N, M0)
  4. In-transit (ITM) are permitted if they are completely resectable. ITM defined as skin or subcutaneous metastases that are > 20 mm from the primary lesion but not beyond the regional nodal basin.
  5. according to version 1.1 criteria (≥10 mm longest diameter for primary lesions and / or ≥10 mm in shortest diameter for lymph nodes as determined by CT imaging) within 2 weeks of the start of study treatment.
  6. Tumour amenable to a newly obtained core of a lesion which has not been previously irradiated. Archival tissue from a past primary or nodal cuSCC lesion (if applicable) or tissue taken for current diagnosis will also be collected.
  7. Previous radiotherapy permitted if performed at a prior site of disease not seen at baseline.
  8. (ECOG) performance status of 0-1
  9. Documented adequate haematological, hepatic, renal, and thyroid function determined by blood pathology
  10. Anticipated of > 12 months
  11. Women of must have a negative serum pregnancy test within 24 hours of the first dose of study treatment or within 72 hours if this is not feasible. Effective should be used for the duration of study treatment and for 5 half-lives (or 5 months) after the last dose. Egg donation (ova, oocytes) should be avoided for the same period. There are no partner-pregnancy or sperm donation avoidance requirements for male patients.

Exclusion criteria

Exclusion Criteria:

  1. Clinical or radiographic evidence of distant
  2. SCC of the eyelid, vulva, penis and perianus
  3. Any to the administration of nivolumab and / or relatlimab
  4. Prior , CTLA-4 (Cytotoxic T-lymphocyte associated protein 4), PDL-1 (Programmed death-ligand 1) or LAG 3 (Lymphocyte-Activation Gene 3) antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment
  5. Active disease or a requirement for chronic therapy other than hormone replacement therapy

    The following are permitted:

    • Vitiligo
    • Type I diabetes mellitus on stable insulin therapy
    • Residual autoimmune hypothyroidism on stable hormone replacement
    • Resolved childhood asthma or atopy
    • Psoriasis not requiring systemic treatment
    • Autoimmune conditions which are not expected to recur in the absence of an external trigger.
  6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent) or any other form of therapy within 14 days prior to the first dose of study treatment.

    The following are permitted:

    • Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.)
    • Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient is on a stable dose
    • Non-absorbed intra-articular steroid injections.
  7. Known additional (unless adequately treated) active within the previous 3 years, except for locally curable cancers that have been apparently cured.

    The following malignancies, if undergone successful definitive resection or curative treatment, are permitted:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ, but excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy
    • Prostatic intraepithelial neoplasia
    • In situ melanoma
    • Atypical melanocytic hyperplasia
    • Multiple primary melanomas
    • Other malignancies for which the patient has been disease free for 3 years, not requiring active anti-cancer therapy.
  8. Uncontrolled or significant cardiovascular disease including, but not limited to any of the following:

    • Myocardial infarction (MI) or stroke/ within the 6 months prior to consent
    • Uncontrolled angina within the 3 months prior to consent
    • Any history of arrhythmias (such as poorly controlled atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    • (corrected QT interval) prolongation > 480 ms
    • History of other clinically significant cardiovascular disease (i.e. cardiomyopathy, congestive heart failure with functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled venous thrombosis, etc)
    • Cardiovascular disease-related requirement for daily supplemental oxygen
    • History of 2 or more M.I.s OR 2 or more coronary revascularisation procedures (regardless of the number of stent placements during each procedure)
    • Patients with history of myocarditis, regardless of aetiology.
  9. Troponin T (TnT) or I (TnI) >2 × institutional (upper limit of normal). Participants with TnT or TnI levels between >1 to 2 × ULN will be permitted if repeat levels within 24 hours are ≤1 ULN. If TnT or TnI levels are between >1 to 2 × ULN within 24 hours, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are \<2 × ULN, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. Notification of the decision to enrol the participant following cardiologist recommendation must be made to the Lead Investigator.
  10. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis or current interstitial lung disease.
  11. Has an active infection requiring systemic therapy.
  12. Has a known history of (HIV). Note: no testing for HIV is required unless mandated by local health authority.
  13. Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  14. Pregnant or breast-feeding females
  15. Concurrent medical or social conditions that may prevent the patient from attending assessments per schedule.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Treatment

    Nivolumab and relatlimab will be administered in a fixed dose combination (FDC). The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. All patients are scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29. Patients without a complete pathological response to neoadjuvant therapy may receive standard of care radiotherapy per multidisciplinary team meeting discussion.

    Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination

Interventions

  • DrugNivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination

    Drug page: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways

    Also known as: Opdualag

06

What researchers measure

Primary outcomes

  1. Pathological complete response rate

    Proportion of patients with a pathological complete response, as determined on the week 6 surgical specimen using the guidelines published by the International Neoadjuvant Melanoma Consortium: Complete pathological response (pCR) = 0% viable tumour cells in the surgical specimen

    Time frame: Week 6

Secondary outcomes

  1. Pathological near pathological response (near pCR), partial response (pPR) and pathological non-response (pNR) rate

    Proportion of patients with each non-pCR response category, as determined on the week 6 surgical specimen using the guidelines published by the International Neoadjuvant Melanoma Consortium (INMC): * Major pathological response (pCR + near-pCR), * Near complete pathological response - (near pCR) - \>0% - ≤10% viable tumour * Partial pathological response (pPR) - \>10 - ≤50% viable tumour * Non pathological response (pNR) - \>50% viable tumour

    Time frame: Week 6

  2. Toxicity and tolerability of neoadjuvant immunotherapy and surgery

    The proportion of patients with adverse events (AE) per Common Terminology Criteria for Adverse Events (CTCAE), from initiation of study treatment until at least 135 days after the end of treatment. Outcome measures include the proportion of patients with each of the following measures: 1. An AE by CTCAE term / grade 2. AEs attributable to neoadjuvant treatment 3. Grade 3/4/5 AEs by AE term 4. The duration of events reported in (a) 5. Delayed study treatment and/or delay surgery due to an AE 6. A requirement to discontinue study treatment early due to an AE 7. Oral or parenteral steroid treatment for immune-related adverse events. 8. Post-operative complications (e.g. seroma formation, wound infection or lymphoedema) and duration of events. 9. Post-operative complications at 3, 12 and 48 weeks using the Clavien-Dindo Classification. 10. Surgeon's assessment of 'operability' and morbidity from baseline and at surgery per INMC questionnaires.

    Time frame: Week 48

  3. Objective response rate to neoadjuvant therapy

    The proportion of patients within each response category, as assessed using RECIST version 1.1, comparing week 6 to baseline CT and MRI. Objective response rate= CR and PR

    Time frame: Week 6

  4. Metabolic response rate to neoadjuvant immunotherapy

    The proportion of patients within each response category, as assessed using the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and the standardised uptake value (SUV) comparing week 6 to baseline positron emission tomography (PET) scan. Metabolic response rate = Complete metabolic response (CMR) and partial metabolic response (PMR).

    Time frame: Week 6

  5. Recurrence-free survival

    The proportion of patients alive and disease free from the time of surgery

    Time frame: 10 years

  6. Disease progression rate

    The proportion of patients alive and with RECIST-defined progression of disease from the date of consent to the first radiographical evidence of local, regional or distant progression. Disease progression which leads to unresectable cutaneous squamous cell carcinoma (cuSCC)

    Time frame: Week 6

  7. Event-free survival rate

    Proportion of patients with EFS defined as the earliest of any of the following events: 1. Time from 1st dose study treatment to disease progression (unresectable stage III or stage IV disease), 2. Time of surgery to recurrence of cuSCC (local, regional or distant) 3. Treatment related death 4. Disease related death

    Time frame: 10 years

  8. Overall survival

    The proportion of patients alive at years 1, 2, 5 and 10, and to actual date of death (in months), from the first dose of study treatment.

    Time frame: 10 years

  9. Patient reported quality of life (QLQ-C30)

    The published scoring for: The European Organization for the Research and Treatment of Cancer Quality of Life of Cancer Patients Questionnaire (QLQ-C30). A 30 item instrument where a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. Changes in patient rated quality of life (QOL) scores using QLQ-C30 are recorded at baseline (within 7 days of first dose of study treatment) and at 6 -12 weekly intervals until the end of year 1 will be measured. The correlation of the QLQ-C30 scores with adverse events will be measured.

    Time frame: 1 year

  10. Patient reported quality of life (EQ-5L-5D)

    The published scoring for: The European Quality of Life (EQ-5L-5D). Each dimension has 5 levels: no problems, some problems, extreme problems. The EQ visual analogue scale (VAS records) the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable, health state' and 'Worst imaginable health state'. Changes in patient rated quality of life (EQ-5D-5L) scores recorded at baseline (within 7 days of first dose of study treatment) and at 6 -12 weekly intervals until the end of year 1 will be measured. The correlation of the EQ-5L-5D scores with adverse events will be measured.

    Time frame: 1 year

  11. Study treatment completion rate and the causes of any missed treatments

    Proportion of patients receiving full neoadjuvant drug treatment per schedule and number of treatments missed. Proportion of patients undergoing planned surgery at week 6. Reasons for incomplete study treatment e.g. adverse event, withdrawn consent, disease progression, patient lost to follow-up.

    Time frame: Week 8

  12. De-escalation of adjuvant radiotherapy.

    Proportion of patients where adjuvant radiotherapy was planned at baseline but who did not need radiotherapy as a result of pathological response and pathologically clear surgical margins.

    Time frame: Week 8

Other outcomes

  1. Identification of tissue and blood biomarkers of response / resistance

    Identification of biomarkers in tumour tissue and blood that may be predicitve of the response or resistance to neoadjuvant immunotherapy.

    Time frame: 1 year

  2. Profile of the gut microbiome from faecal samples and relationship to response and toxicities.

    Identification of the type and abundance of gut microbes and the correlation with treatment response and incidence of treatment-related toxicities.

    Time frame: Week 6

  3. The pathological response to RECIST, immune related response criteria and PERCIST response

    Proportion of patients with concordance across all tumour evaluations

    Time frame: Week 6

  4. Assessment of the response to neoadjuvant using the immune-related response criteria (irRC) and correlate the assessment with the RECIST 1.1 response at each timepoint

    Bi-dimensional measurements of all target lesions per irRC guidelines

    Time frame: Week 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Sep 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2024
First posted
Mar 1, 2024
StartActual
Jun 21, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Jul 2036
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06288191
Lead sponsor
Melanoma Institute Australia
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Jun 21, 2024
Primary completion
Sep 2026 (estimated)
Completion
Jul 2036 (estimated)
Last update
Jul 8, 2026

Study contacts

Monica Osorio
Contact
monica.osorio@melanoma.org.au
+61 2 9911 7296
Maria Gonzalez
Contact
maria.gonzalez@melanoma.org.au
+61 2 9911 7200
Ines Da Silva
principal investigator · Melanoma Instiute Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion